-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Ranked Among the Top 20 on the “2025 China Chemical Pharmaceutical R&D Strength Ranking”
Category:
发布时间：2025-06-20
【概要描述】
On the morning of June 20, the “2025 PDI Pharmaceutical R&D and Innovation Conference & Release Ceremony of the Top 100 Chinese Pharmaceutical R&D Companies” was grandly held at the Chongqing Science Hall in the mountain city of Chongqing, drawing intense attention from the pharmaceutical industry with its electrifying energy and irresistible appeal. Thanks to its robust R&D capabilities and groundbreaking innovations, Shijiazhuang Sihua Pharmaceutical Group was recognized on two prestigious lists—the “2025 China Pharmaceutical R&D Comprehensive Strength Ranking” and the “2025 China Chemical Pharmaceutical R&D Strength Ranking”—where it ranked 34th and 16th, respectively.
On the morning of June 20, the Science Hall in the mountain city of Chongqing buzzed with excitement and charisma as the highly anticipated “2025 PDI Pharmaceutical R&D Innovation Conference and China’s Top 100 Pharmaceutical R&D Rankings Launch Event” was grandly held. Thanks to its robust R&D capabilities and groundbreaking innovations, Shijiazhuang Sihua Pharmaceutical Group secured a place on both the “2025 China Pharmaceutical R&D Comprehensive Strength Ranking” and the “2025 China Chemical Pharmaceutical R&D Strength Ranking,” ranking 34th and 16th, respectively.
According to available information, the China Pharmaceutical R&D Strength Ranking is initiated by Yaozhi Network. Since its inaugural release at the 2016 China Pharmaceutical R&D & Innovation Conference, the ranking has evolved over ten iterations and has now become the most authoritative and influential evaluation system in China’s pharmaceutical and healthcare industry. The ranking is compiled by the Expert Review Committee of the PDI Pharmaceutical R&D & Innovation Conference, which assigns scores based on key metrics such as the number of drug applications approved in 2024, R&D investment, overall ranking score, completion of clinical trials, and patent holdings. The final results are presented across four main categories: the Overall Ranking, the Traditional Chinese Medicine Ranking, the Chemical Drug Ranking, and the Biologics Ranking. In recent years, Shijiazhuang Sihua Pharmaceutical Group has consistently been included in this series of rankings, reflecting the industry’s recognition of its innovative capabilities and underscoring the company’s accelerating ascent into the forefront of China’s pharmaceutical innovation.
As a leading enterprise in China’s pharmaceutical industry, Shijiazhuang Sihua Pharmaceutical Group has consistently upheld its original aspiration of “producing high-quality medicines for the people.” With innovation as its core driving force, the company focuses on unmet clinical and market needs, adopts a differentiated R&D pipeline strategy, and actively builds a product innovation system that is led by innovative drugs, underpinned by specialty chemical formulations and active pharmaceutical ingredients, and extended into high-end pharmaceutical packaging materials and specialized biologics.
In recent years, the company has leveraged its status as a national-level enterprise technology center and its innovative consortia established in collaboration with universities and research institutes to steadfastly pursue an R&D and innovation strategy that combines imitation with original innovation. Focusing on key therapeutic areas such as antiviral, antibacterial, anticancer, neurological, cardiovascular, gastrointestinal, anesthetic, and dialysis treatments, the company has intensified collaborative innovation, resulting in markedly improved R&D and commercialization efficiency and robust growth momentum. In 2024, the company received approval for 82 new products. To date, a total of 132 drug varieties comprising 177 dosage forms have either passed or been deemed to have passed the consistency evaluation, with the number of new-product applications and approvals remaining at the forefront of the industry—providing ample impetus for the company’s competitive development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091